News & Updates

In the 18-month results from the phase IIIb TRAILBLAZER-ALZ 6 trial, the newly recommended dosing schedule of donanemab results in a significant reduction in the incidence of amyloid-related imaging abnormalities with effusion/oedema (ARIA-E) compared with standard dosing in adults with early symptomatic Alzheimer’s disease (AD).

The use of tirzepatide in a real-world setting demonstrates a favourable safety profile and results in weight loss, lower insulin requirements, and better glycaemic measurements among patients with type 1 diabetes (T1D), as shown in a study presented at EASD 2025.

Ritlecitinib 50 mg demonstrates clinically meaningful efficacy up to 36 months in individuals with alopecia areata (AA) in the phase IIb/III ALLEGRO and ongoing phase III ALLEGRO-LT trials.